SMN1 mRNA-based therapy (Genencine Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameSMN1 mRNA-based therapy (Genencine Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionSurvival motor neuron protein stimulants
TargetsSurvival motor neuron protein
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGenencine Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenencine Therapeutics LLC
Active IndicationsN/A
Inactive IndicationsMuscular Atrophy, Spinal

Other Information

ATC CodeN/A
Related LinksN/A